title: [Evaluation of systemic chemotherapy for unresectable gallbladder carcinoma].
abstract: We analyzed a treatment outcome and the effect of systemic chemotherapy for patient with unresectable gallbladder carcinoma. Sixteen patients were investigated. Gemcitabine (GEM) was administrated for fifteen patients as the first-line chemotherapy. S-1 was administrated for ten patients as the second-line chemotherapy. The response rate and tumor control rate of the first-line GEM were 14.3% and 78.6%, respectively. The median progression free time of the first-line GEM was 6.0 months. The response rate and tumor control rate of the second-line S-1 were respectively 20.0% and 30.0%. The median progression free time of the second-line S-1 was 1.8 months. The median survival time of all cases was 14.9 months. The outcome of systemic chemotherapy for patients with unresectable gallbladder carcinoma in our hospital was feasible compared with past reports.
authors.affiliation: Dept. of Surgery, Toyonaka Municipal Hospital.
authors.forename: Junzo
authors.initials: J
authors.lastname: Shimizu
authors.forename: Keizo
authors.initials: K
authors.lastname: Dono
authors.forename: Shiki
authors.initials: S
authors.lastname: Fujino
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Hata
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kitahara
authors.forename: Takehiro
authors.initials: T
authors.lastname: Yanagawa
authors.forename: Koji
authors.initials: K
authors.lastname: Munakata
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Kaori
authors.initials: K
authors.lastname: Takamoto
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nagai
authors.forename: Masakazu
authors.initials: M
authors.lastname: Miyake
authors.forename: Taishi
authors.initials: T
authors.lastname: Hata
authors.forename: Kenshu
authors.initials: K
authors.lastname: Kawanishi
authors.forename: Kimimasa
authors.initials: K
authors.lastname: Ikeda
authors.forename: Junya
authors.initials: J
authors.lastname: Fujita
authors.forename: Kenzo
authors.initials: K
authors.lastname: Akagi
authors.forename: Takashi
authors.initials: T
authors.lastname: Iwazawa
authors.forename: Masashi
authors.initials: M
authors.lastname: Kitada
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimano
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005706:Gallbladder Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis; D005641:Tegafur / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine